Equities Analysts Issue Forecasts for Lipocine Q1 Earnings

Lipocine Inc. (NASDAQ:LPCN) – Equities research analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for shares of Lipocine in a research note issued to investors on Monday, March 30th. HC Wainwright analyst Y. Chen now anticipates that the specialty pharmaceutical company will post earnings per share of ($0.51) for the quarter, up from their prior forecast of ($0.60). HC Wainwright has a “Neutral” rating on the stock. HC Wainwright also issued estimates for Lipocine’s Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.91) EPS.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $15.00.

Lipocine Stock Performance

LPCN stock traded up $0.04 during mid-day trading on Tuesday, reaching $1.98. The company had a trading volume of 1,341,748 shares, compared to its average volume of 299,658. The company has a market capitalization of $14.45 million, a price-to-earnings ratio of -1.17 and a beta of 1.09. The firm has a fifty day simple moving average of $8.10 and a 200 day simple moving average of $5.78. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.

Institutional Trading of Lipocine

Institutional investors have recently modified their holdings of the business. Citadel Advisors LLC purchased a new stake in shares of Lipocine in the third quarter valued at approximately $41,000. Jane Street Group LLC purchased a new stake in shares of Lipocine in the fourth quarter valued at approximately $85,000. Renaissance Technologies LLC boosted its stake in shares of Lipocine by 3.6% in the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Lipocine in the fourth quarter valued at approximately $441,000. Finally, Geode Capital Management LLC boosted its stake in shares of Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares in the last quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director John W. Higuchi bought 123,000 shares of the stock in a transaction on Monday, April 6th. The shares were bought at an average cost of $2.05 per share, for a total transaction of $252,150.00. Following the purchase, the director owned 163,797 shares of the company’s stock, valued at $335,783.85. This trade represents a 301.49% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Mahesh V. Patel bought 25,000 shares of the stock in a transaction on Monday, April 6th. The stock was bought at an average price of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the purchase, the chief executive officer directly owned 160,679 shares in the company, valued at approximately $326,178.37. The trade was a 18.43% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 173,000 shares of company stock worth $353,400 in the last 90 days. 6.35% of the stock is currently owned by company insiders.

More Lipocine News

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: CEO Mahesh Patel purchased 25,000 shares (~$2.03 avg), increasing his stake ~18%. Insider buying from senior management often signals confidence in the company’s prospects and can support short-term buying interest. Read More.
• Positive Sentiment: Director John W. Higuchi bought 123,000 shares (~$2.05 avg), a large increase in his holding. Substantial director-level purchases can amplify the positive signal from the CEO buy and attract momentum-seeking investors. Read More.
• Neutral Sentiment: HC Wainwright raised its EPS estimates across Q1–Q4 and cut its FY2026 loss forecast to ($1.91) from ($2.27) while maintaining a “Neutral” rating — model improvements but no upgrade. The revisions reduce downside in institutional models but leave the street view unchanged for now.
• Neutral Sentiment: Institutional activity shows modest new/added positions (Citadel, Jane Street, Renaissance, Boothbay, Geode). Total institutional ownership remains low (~9.1%), so inflows are supportive but not yet a major demand driver. Read More.
• Negative Sentiment: Johnson Fistel announced an investigation into potential shareholder claims against Lipocine’s executives. The probe raises litigation risk and could create headline-driven volatility or costs if it advances. Read More.
• Negative Sentiment: Despite a recent quarterly beat (reported March 10), Lipocine remains unprofitable with large negative margins and a history of losses — a structural risk that keeps valuation speculative and makes the stock sensitive to fundraising, clinical progress, or regulatory news. Read More.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.